Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Cancer Research at the
Helen F. Graham Cancer Center
& Research Institute

NCORP and Pharmaceutical Clinical Trials

NCORP Clinical Trials

In 1987, ChristianaCare was awarded funding as a Community Clinical Oncology Program (CCOP), which provided the opportunity for physicians throughout Delaware to enroll patients in national clinical trials. Additionally, it offered an opportunity to increase minority and underserved community clinical trial participation. Since joining CCOP, the Helen F. Graham Cancer Center & Research Institute has become one of the largest clinical trial programs among community-based hospitals in the country, with some 100 active clinical trials in most kinds of cancer. The Graham Cancer Center is also one of the top enrollers in cancer clinical trials.

In 2014, a number of CCOP’s merged to form NCORP, the National Cancer Institute’s Community Oncology Research Program. NCORP is a national network of investigators, cancer care providers, academic institutions, and other organizations. NCORP continues the work of CCOP’s by offering multi-site cancer clinical trials and studies to diverse populations in community-based healthcare systems across the United States and Puerto Rico. The goal of NCORP is to bring cancer clinical trials – cancer control, prevention, screening, treatment, and imaging – as well as cancer care delivery research, to individuals in their own communities, thus generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.

The mission of the Graham Cancer Center is to reduce the incidence, morbidity and mortality of cancer in our community and to improve quality of life for those living with cancer. Participation in NCORP helps us to realize these goals.

Pharmaceutical Clinical Trials

The Graham Cancer Center offers a robust pharmaceutical trials program that conducts Phase I, II and III chemotherapy and immunotherapy trials in collaboration with private industry and university research centers across the country. Many of these studies give our patients the opportunity for leading-edge cancer treatments, tailored to their particular cancer without leaving our community.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.